Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
- 19 December 2024
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (3) , 439-447
Abstract
Background: Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis and affects the prognosis of lung cancer. In this study, we investigated whether the anti-FDX1 autoantibody could serve as a novel biomarker for the detection of non–small cell lung cancer (NSCLC). Methods: A total of 1,155 plasma samples were divided into the verification and validation groups. The expression levels of the anti-FDX1 autoantibody in 414 patients with NSCLC, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC) were detected using ELISA. Western blotting and immunofluorescence analyses were performed to confirm the ELISA results. Results: Plasma anti-FDX1 autoantibody levels were significantly higher in patients with NSCLC than in patients with BPN and NCs in the verification and validation groups. The ELISA results were confirmed by Western blotting and immunofluorescence. The anti-FDX1 autoantibody distinguished NSCLC from NC and BPN with an AUC (95% confidence interval) of 0.806 (0.772–0.839) and 0.627 (0.584–0.670), respectively. Conclusions: Our study demonstrated the potential benefits of the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection. Impact: These findings suggested that the anti-FDX1 autoantibody may facilitate the detection of NSCLC.Keywords
All Related Versions
This publication has 37 references indexed in Scilit:
- High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD)Journal of Cancer Research and Clinical Oncology, 2022
- Efficacy of autoantibodies combined with tumor markers in the detection of lung cancerJournal of Clinical Laboratory Analysis, 2022
- Tumour- associated autoantibodies as prognostic cancer biomarkers- a reviewAutoimmunity Reviews, 2022
- Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapySeminars in Cancer Biology, 2018
- p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinomaAnnals of Gastroenterological Surgery, 2018
- Lung cancer: current therapies and new targeted treatmentsThe Lancet, 2017
- Autoantibody Production in Cancer—The Humoral Immune Response toward Autologous Antigens in Cancer PatientsAutoimmunity Reviews, 2016
- Carcinoembryonic antigen (CEA) as tumor marker in lung cancerLung Cancer, 2012
- Tobacco smoking and cancer: a brief review of recent epidemiological evidenceLung Cancer, 2004
- The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissuesSeminars in Cancer Biology, 1999